Mifepristone causing complete remission of rapidly advancing leukemia with measurement of progesterone-induced blocking factor.

Abstract

BACKGROUND:

Mifepristone has been demonstrated to cause palliation from murine and human cancer, even in cancers not known to be positive for expression of progesterone receptors. The aim of the present study was to determine if rapidly advancing chronic lymphocytic leukemia responds to mifepristone therapy, and if so, is this effect related to increased expression of the progesterone-induced blocking factor?

CASE REPORT:

An 81-year-old woman with chronic lymphocytic leukemia whose condition progressed to the acute rapidly progressing stage agreed to be exclusively treated orally with 200 mg mifepristone daily.

RESULTS:

The patient showed a dramatic improvement after a short exposure time to mifepristone. Complete remission has persisted so far for 12 months on exclusive mifepristone therapy. Her PIBF levels were normal before mifepristone therapy and did not change after treatment.

CONCLUSION:

Mifepristone can provide marked improvement of human leukemia even in the absence of increased serum PIBF levels.

• Authors: Jerome H Check, Diane Check, Rachael Cohen, Mojirayo Sarumi
• Journal: Anticancer research (Anticancer Res) Vol. 34 Issue 5 Pg. 2413-6 (May 2014) ISSN: 1791-7530 [Electronic] Greece
• PMID: 24778052 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• PIBF1 protein, human
• Pregnancy Proteins
• Suppressor Factors, Immunologic
• Mifepristone

Topics

• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (blood, drug therapy)
• Mifepristone (therapeutic use)
• Pregnancy Proteins (blood)
• Remission Induction
• Suppressor Factors, Immunologic (blood)